"Antiviral Agents" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Agents used in the prophylaxis or therapy of VIRUS DISEASES. Some of the ways they may act include preventing viral replication by inhibiting viral DNA polymerase; binding to specific cell-surface receptors and inhibiting viral penetration or uncoating; inhibiting viral protein synthesis; or blocking late stages of virus assembly.
Descriptor ID |
D000998
|
MeSH Number(s) |
D27.505.954.122.388
|
Concept/Terms |
Antiviral Agents- Antiviral Agents
- Agents, Antiviral
- Antivirals
- Antiviral Drugs
- Drugs, Antiviral
|
Below are MeSH descriptors whose meaning is more general than "Antiviral Agents".
Below are MeSH descriptors whose meaning is more specific than "Antiviral Agents".
This graph shows the total number of publications written about "Antiviral Agents" by people in this website by year, and whether "Antiviral Agents" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
1994 | 1 | 2 | 3 |
1995 | 9 | 2 | 11 |
1996 | 10 | 3 | 13 |
1997 | 8 | 4 | 12 |
1998 | 9 | 2 | 11 |
1999 | 9 | 4 | 13 |
2000 | 2 | 3 | 5 |
2001 | 7 | 5 | 12 |
2002 | 8 | 6 | 14 |
2003 | 6 | 7 | 13 |
2004 | 8 | 3 | 11 |
2005 | 6 | 4 | 10 |
2006 | 14 | 6 | 20 |
2007 | 14 | 7 | 21 |
2008 | 5 | 6 | 11 |
2009 | 7 | 6 | 13 |
2010 | 10 | 3 | 13 |
2011 | 18 | 6 | 24 |
2012 | 8 | 3 | 11 |
2013 | 9 | 4 | 13 |
2014 | 20 | 1 | 21 |
2015 | 21 | 4 | 25 |
2016 | 15 | 1 | 16 |
2017 | 9 | 6 | 15 |
2018 | 5 | 3 | 8 |
2019 | 9 | 6 | 15 |
2020 | 8 | 10 | 18 |
2021 | 10 | 11 | 21 |
2022 | 1 | 4 | 5 |
2023 | 1 | 7 | 8 |
2024 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Antiviral Agents" by people in Profiles.
-
Renal outcomes in adults with HBV, HIV and HBV/HIV coinfection after 3 years of antiviral therapy in urban Tanzania. J Antimicrob Chemother. 2024 Jan 03; 79(1):36-45.
-
Twelve-month kidney and liver outcomes of kidney transplantation from Hepatitis C Viremic deceased donors to aviremic recipients. Transpl Infect Dis. 2024 Feb; 26(1):e14213.
-
Acquired resistance to KRAS G12C small-molecule inhibitors via genetic/nongenetic mechanisms in lung cancer. Sci Adv. 2023 10 13; 9(41):eade3816.
-
Efficacy and Safety of Sofosbuvir/Velpatasvir Plus Ribavirin in Patients with Hepatitis C Virus-Related Decompensated Cirrhosis. Viruses. 2023 09 29; 15(10).
-
Development of Masitinib Derivatives with Enhanced Mpro Ligand Efficiency and Reduced Cytotoxicity. Molecules. 2023 Sep 15; 28(18).
-
Antiviral HIV-1 SERINC restriction factors disrupt virus membrane asymmetry. Nat Commun. 2023 07 20; 14(1):4368.
-
Cytomegalovirus Hepatitis in Allograft Livers May Show Histologic Features of Acute Cellular Rejection. Arch Pathol Lab Med. 2023 06 01; 147(6):655-664.
-
Prolonged Interferon-Stimulated Gene and Protein Signatures in Multiple Sclerosis Induced by PEGylated IFN-ß-1a Compared to Non-PEGylated IFN-ß-1a. J Interferon Cytokine Res. 2023 03; 43(3):108-120.
-
Treatment options for severe or refractory mpox virus infection in patients with advanced HIV. Int J STD AIDS. 2023 05; 34(6):366-373.
-
Association between sustained virological response and clinical outcomes in patients with hepatitis C infection and hepatocellular carcinoma. Cancer. 2022 10 01; 128(19):3470-3478.